Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
21 oct. 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
12 oct. 2021 13h35 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
07 oct. 2021 09h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
05 oct. 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering
29 sept. 2021 16h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Announces $7.0 Million Registered Direct Offering
27 sept. 2021 09h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360
21 sept. 2021 09h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Announces Special Virtual Investor Presentation
14 sept. 2021 08h59 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat...
Skye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to...
Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference
11 août 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat...